LaBelle A - Search Results

1

Procedural learning improvements after six weeks of clozapine treatment.

Purdon SE, Woodward ND, Mintz A, LaBelle A. Purdon SE, et al. Among authors: labelle a. Schizophr Res. 2002 Jan 1;53(1-2):165-6. doi: 10.1016/s0920-9964(00)00193-6. Schizophr Res. 2002. PMID: 11728847 No abstract available.

2

Neuropsychological change in schizophrenia after 6 weeks of clozapine.

Purdon SE, Labelle A, Boulay L. Purdon SE, et al. Among authors: labelle a. Schizophr Res. 2001 Mar 1;48(1):57-67. doi: 10.1016/s0920-9964(00)00101-8. Schizophr Res. 2001. PMID: 11278154 Clinical Trial.

3

Risperidone treatment for severe negative symptoms.

Jones BD, Purdon SE, Labelle A, Finlayson R. Jones BD, et al. Among authors: labelle a. Can J Psychiatry. 1994 Aug;39(6):381. doi: 10.1177/070674379403900616. Can J Psychiatry. 1994. PMID: 7527292 No abstract available.

4

Risperidone in the treatment of pervasive developmental disorder.

Purdon SE, Lit W, Labelle A, Jones BD. Purdon SE, et al. Among authors: labelle a. Can J Psychiatry. 1994 Sep;39(7):400-5. doi: 10.1177/070674379403900703. Can J Psychiatry. 1994. PMID: 7527293

5

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.

Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD. Purdon SE, et al. Among authors: labelle a. Arch Gen Psychiatry. 2000 Mar;57(3):249-58. doi: 10.1001/archpsyc.57.3.249. Arch Gen Psychiatry. 2000. PMID: 10711911 Clinical Trial.

6

Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol.

Purdon SE, Malla A, Labelle A, Lit W. Purdon SE, et al. Among authors: labelle a. J Psychiatry Neurosci. 2001 Mar;26(2):137-49. J Psychiatry Neurosci. 2001. PMID: 11291531 Free PMC article. Clinical Trial.

7

Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment.

Knott V, Labelle A, Jones B, Mahoney C. Knott V, et al. Among authors: labelle a. Schizophr Res. 2001 May 30;50(1-2):41-53. doi: 10.1016/s0920-9964(00)00165-1. Schizophr Res. 2001. PMID: 11378313

8

Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers.

Joober R, Rouleau GA, Lal S, Dixon M, O'Driscoll G, Palmour R, Annable L, Bloom D, Lalonde P, Labelle A, Benkelfat C. Joober R, et al. Among authors: labelle a. Schizophr Res. 2002 Jan 15;53(3):229-38. doi: 10.1016/s0920-9964(01)00279-1. Schizophr Res. 2002. PMID: 11738536

9

MMN responsivity to manipulations of frequency and duration deviants in chronic, clozapine-treated schizophrenia patients.

Horton J, Millar A, Labelle A, Knott VJ. Horton J, et al. Among authors: labelle a. Schizophr Res. 2011 Mar;126(1-3):202-11. doi: 10.1016/j.schres.2010.11.028. Epub 2010 Dec 30. Schizophr Res. 2011. PMID: 21194893

10

Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients.

Joober R, Rouleau GA, Lal S, Bloom D, Lalonde P, Labelle A, Benkelfat C. Joober R, et al. Among authors: labelle a. Schizophr Res. 2005 Sep 1;77(1):35-41. doi: 10.1016/j.schres.2005.01.008. Schizophr Res. 2005. PMID: 16005383

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

211 results

Search Page

Filters